• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Emerging roles of growth differentiation factor-15 in brain disorders (Review)
Exp Ther Med. 2021 Nov;22(5):1270. doi: 10.3892/etm.2021.10705. Epub 2021 Sep 7.ABSTRACTBrain disorders, such as Alzheimer's and Parkinson's disease and cerebral stroke, are an important contributor to mortality and disability worldwide, where their pathogenesis is currently a topic of intense research. The mechanisms underlying the development of brain disorders are complex and vary widely, including aberrant protein aggregation, ischemic cell necrosis and neuronal dysfunction. Previous studies have found that the expression and function of growth differentiation factor-15 (GDF15) is closely associated with the incidence ...
Source: Experimental and Therapeutic Medicine - October 1, 2021 Category: General Medicine Authors: Wei-Wei Jiang Zi-Zhen Zhang Ping-Ping He Li-Ping Jiang Jin-Zhi Chen Xing-Ting Zhang Mi Hu Yang-Kai Zhang Xin-Ping Ouyang Source Type: research

Prostate Cancer Drug Could Be ' Game Changing, ' Researchers Say
FRIDAY, May 29, 2020 -- For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke, a clinical trial has found. The drug, called relugolix, is...
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

To the Horizon: The Brink of an AI Revolution in Prostate Cancer?
Noorbakhsh-Sabet et al.1 published an excellent review in The American Journal of Medicine summarizing the potential of artificial intelligence (AI) in medicine. They describe wide utility (e.g. in dermatology and stroke), but do not consider surgery and urology, which embrace cutting-edge technology, including fusion-biopsy and robotics,2 and will be early AI adopters. Indeed, prostate cancer creates a huge health care burden, thus being ideal for AI transformation.
Source: The American Journal of Medicine - January 16, 2020 Category: General Medicine Authors: Joseph M. Norris, Asif Raza Tags: Letter Source Type: research

Pharmacological treatment of NASH.
Abstract Lifestyle modifications, especially weight loss, are efficient on NASH liver injury, however rarely followed in clinical practice. The target population of pharmacologic treatments is represented by patients with NASH and fibrosis. Out of histological improvement, efficacy of treatments should be assessed through liver morbi-mortality benefit, but also on extrahepatic events, such as cardiovascular. Among anti-diabetic treatments, glitazones et GLP-1 agonists have shown efficacy on histological liver injury. Vitamin E is efficient on liver injury but at the cost of prostate cancer and stroke over risk. Ab...
Source: Presse Medicale - November 18, 2019 Category: General Medicine Authors: Serfaty L Tags: Presse Med Source Type: research

Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - August 21, 2019 Category: General Medicine Source Type: research

Obituary Philip Majerus
Physician and biochemist who showed small doses of aspirin reduce the risk of heart attack and stroke. Born on July 10, 1936, in Chicago, IL, USA, he died with prostate cancer on June 8, 2016, in University City, MO, USA, aged 79 years.
Source: LANCET - July 29, 2016 Category: Journals (General) Authors: Alison Snyder Tags: Obituary Source Type: research

Plasma testosterone, obesity, metabolic syndrome and diabetes.
Abstract The frequency of diabetes and/or metabolic syndrome rises concurrently with that of body mass index (BMI). In adult men, plasma testosterone level changes evolve inversely to that of BMI. Plasma total testosterone, sex hormone-binding globulin (SHBG) and free testosterone are significantly lower in adult men with a clinical and biological pattern of metabolic syndrome (MetS) than in those without such a pattern. After adjustment for confounding factors, diabetes type 2 (DT2) remains associated with a significant decrease of plasma testosterone level. The androgenic blockade, used as a treatment for dissem...
Source: Presse Medicale - November 21, 2013 Category: Journals (General) Authors: Prévost G, Eas F, Kuhn JM Tags: Presse Med Source Type: research